AbbVie Inc. Cost of Revenue

Cost of Revenue of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cost of Revenue growth rates and interactive chart. Cost of revenue refers to the direct costs attributable to the production of the goods or supply of services by an entity. It is also commonly known as the “cost of goods sold (COGS)”. Cost of sales measures the cost of goods produced or services provided in a period by an entity. It includes the cost of the direct materials used in producing the goods, direct labor costs used to produce the good, along with any other direct costs associated with the production of goods. In case of services cost of sales includes the labor cost or salaries of the employees and other directly attributable costs. Cost of sales does not include indirect expenses such as distribution costs and marketing costs. It appears on the income statement and is deducted from the sales revenue for the calculation of gross profit (or gross margin).


Highlights and Quick Summary

  • Cost of Revenue for the quarter ending December 30, 2019 was $2.01 Billion (a 4.48% increase compared to previous quarter)
  • Year-over-year quarterly Cost of Revenue increased by 18.42%
  • Annual Cost of Revenue for 2019 was $7.44 Billion (a -3.61% decrease from previous year)
  • Annual Cost of Revenue for 2018 was $7.72 Billion (a 9.6% increase from previous year)
  • Annual Cost of Revenue for 2017 was $7.04 Billion (a 20.75% increase from previous year)
  • Twelve month Cost of Revenue ending December 30, 2019 was $7.44 Billion (a -0.21% decrease compared to previous quarter)
  • Twelve month trailing Cost of Revenue decreased by -0.61% year-over-year
Trailing Cost of Revenue for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
$7.44 Billion $7.46 Billion $7.37 Billion $7.49 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cost of Revenue of AbbVie Inc.

Most recent Cost of Revenueof ABBV including historical data for past 10 years.

Interactive Chart of Cost of Revenue of AbbVie Inc.

AbbVie Inc. Cost of Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $2,006.0 $1,920.0 $1,819.0 $1,694.0 $7,439.0
2018 $2,022.0 $1,835.0 $1,934.0 $1,927.0 $7,718.0
2017 $2,281.0 $1,616.0 $1,529.0 $1,616.0 $7,042.0
2016 $1,554.0 $1,504.0 $1,405.0 $1,369.0 $5,832.0
2015 $1,475.0 $1,167.0 $916.0 $942.0 $4,500.0
2014 $1,119.0 $1,094.0 $1,113.0 $1,100.0 $4,426.0
2013 $1,282.0 $1,092.0 $1,054.0 $1,153.0 $4,581.0
2012 $1,265.0 $1,014.0 $1,073.0 $1,156.0 $4,508.0
2011 $3,431.69 $1,207.31 $4,639.0
2010 $4,293.0
2009 $4,056.39

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.